RJA
PACB icon

Raymond James & Associates’s Pacific Biosciences PACB Stock Holding History

Raymond James & Associates’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$201K Buy
118,197
+8,430
+8% +$13.8K ﹤0.01% 3637
2024
Q2 		$150K Buy
109,767
+23,161
+27% +$46.8K ﹤0.01% 3666
2024
Q1 		$325K Buy
86,606
+19,213
+29% +$112K ﹤0.01% 3333
2023
Q4 		$661K Buy
67,393
+12,373
+22% +$101K ﹤0.01% 2781
2023
Q3 		$459K Sell
55,020
-18,726
-25% -$214K ﹤0.01% 2951
2023
Q2 		$981K Sell
73,746
-4,636
-6% -$56.3K ﹤0.01% 2488
2023
Q1 		$908K Sell
78,382
-7,078
-8% -$70.4K ﹤0.01% 2510
2022
Q4 		$699K Sell
85,460
-9,630
-10% -$83K ﹤0.01% 2651
2022
Q3 		$552K Buy
95,090
+1,365
+1% +$7.83K ﹤0.01% 2796
2022
Q2 		$414K Sell
93,725
-17,961
-16% -$109K ﹤0.01% 3026
2022
Q1 		$1.02M Buy
111,686
+813
+0.7% +$9.36K ﹤0.01% 2583
2021
Q4 		$2.27M Sell
110,873
-22,300
-17% -$538K ﹤0.01% 2089
2021
Q3 		$3.4M Buy
133,173
+3,214
+2% +$95.2K ﹤0.01% 1743
2021
Q2 		$4.54M Sell
129,959
-19,610
-13% -$570K ﹤0.01% 1549
2021
Q1 		$4.98M Buy
149,569
+46,782
+46% +$1.64M 0.01% 1427
2020
Q4 		$2.67M Sell
102,787
-20,018
-16% -$340K ﹤0.01% 1718
2020
Q3 		$1.21M Buy
122,805
+74,394
+154% +$428K ﹤0.01% 2063
2020
Q2 		$167K Buy
+48,411
New +$165K ﹤0.01% 3180
2019
Q4 		– Sell
-12,000
Closed -$62K – 3728
2019
Q3 		$62K Hold
12,000
– – ﹤0.01% 3451
2019
Q2 		$73K Hold
12,000
– – ﹤0.01% 3451
2019
Q1 		$87K Buy
+12,000
New +$86.8K ﹤0.01% 3416

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Raymond James & Associates's PACB Position: Q3 2024 in Review

Raymond James & Associates increased its Pacific Biosciences (PACB) stake by 7.7% in Q3 2024, buying an estimated $13.8K and bringing the position to 118,197 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #3637.

Raymond James & Associates first reported a position in PACB in Q1 2019 and has held it in 21 quarters since. The position peaked at $4.98M in Q1 2021. 226 funds tracked by Wall St. Rank hold PACB as of Q3 2024.

  • Raymond James & Associates held 118,197 shares of Pacific Biosciences worth $201K as of Q3 2024.
  • Raymond James & Associates bought 8,430 Pacific Biosciences shares in Q3 2024, an estimated $13.8K.
  • Pacific Biosciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3637 holding.
  • Raymond James & Associates first reported a position in Pacific Biosciences in Q1 2019 and has held it in 21 quarters since.
  • Raymond James & Associates's Pacific Biosciences position peaked at $4.98M in Q1 2021.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.